Drug Profile
Research programme: anti-obesity compounds - SIDR
Alternative Names: Anti-obesity compounds research programme - SIDRLatest Information Update: 05 Nov 2002
Price :
$50
*
At a glance
- Originator Strathclyde Institute for Drug Research
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 05 Nov 2002 Discontinued - Preclinical for Obesity in United Kingdom (unspecified route)
- 01 Sep 2000 Ths programme is available for licensing (http://www.sidr.org)
- 01 Sep 2000 Preclinical development for Obesity in United Kingdom (Unknown route)